The 2025 International Medical Device Import Showcase, organized by the Taipei Importers & Exporters Association (IEAT), was an important event for Czech companies in the medical technology sector. This was the second time that Czech companies participated in this influential B2B event, which took place on September 26, 2025. The event attracted over 450 professional buyers and showcased 14 international medical device brands from countries such as Israel, South Korea, the US states of Montana, New Mexico, Georgia, and Czechia. Czech companies EGO Zlín (profile in traditional Chinese), specializing in emergency and long-term care medical devices, and Drillbone (profile in traditional Chinese), offering unique orthopedic surgical instruments, presented their innovative solutions to potential Taiwanese partners.

Taiwan has become an essential hub for medical innovation, and the IEAT matchmaking platform plays a pivotal role in connecting international companies with Taiwanese partners. The event offered an invaluable opportunity for Czech firms to explore business opportunities, not only in Taiwan but also in the broader Asia-Pacific region.

Additional information for Taiwanese interested in Czech medical industry

The Czech medical technology market is rapidly expanding and is projected to reach US$2.15 billion in revenue by 2025, with over 400 enterprises contributing to this growth. The largest segment within this market is medical devices, which is expected to have a market volume of US$1.81 billion in 2025. Looking ahead, the Czech medical technology sector is expected to continue its growth trajectory, with a projected annual growth rate (CAGR) of 3.95% from 2025 to 2030, leading to a market volume of US$2.61 billion by 2030.

Czechia has a long-standing history of achievements in medical sciences, from Gregor Johann Mendel’s discovery of the laws of heredity to the development of the first table-top electron microscope by Armin Delong and Otto Wichterle’s invention of soft contact lenses. In recent years, Czech research has focused on molecular genetics, cell and tissue therapies, diagnostics, and biomedical engineering.

The Czech healthcare industry benefits from a robust research infrastructure, with significant government investment—over EUR 3 billion in the past decade—focused on strengthening research capacities across the country. Czech research teams are internationally recognized, particularly in AI in healthcare, immunology, biochemistry, cardiology, and nanotechnology. These innovations are reshaping healthcare efficiency and improving patient care.

The Czech Republic´s strong regulatory framework, coupled with its membership in the European Union, provides Taiwanese companies with access to a well-established consumer market of 450 million people across Europe. Czechia also offers tax relief for R&D and investment incentives for high-value-added activities, making it an attractive location for international collaborations in medical research and development.

Companies like Teva Pharmaceutical, Lonza, MSD, Johnson & Johnson, Olympus operating, and TermoFisher Scientific are already well-established in the Czech market, highlighting the country´s appeal as a hub for medical and diagnostic devices. With a continued emphasis on Innovation and high-quality medical products, the Czech medical technology sector offers significant potential for bilateral cooperation between Czech and Taiwanese companies, creating opportunities to explore new markets in Central and Eastern Europe and beyond.

For more information on potential collaborations or to explore opportunities in the Czech medical sector, Taiwanese businesses can reach out to the Czech Economic and Cultural Office in Taipei (Taipei.commerce@mzv.gov.cz).

 

Author: Katerina Heinischova, Head of Economic Section, Czech Economic and Cultural Office in Taipei